Developer docs
API playgroundTry for free, no card

Search company profiles

7wire Ventures

Full company profile

uuid0000f5f

Namestring
7wire Ventures
Legal namestring
7wire Ventures
Websiteurl
http://7wireventures.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

7wire Ventures is a Chicago-based, privately-held venture capital firm founded circa 2013-2014 by Glen Tullman and Lee Shapiro, both former senior executives at Allscripts. The firm invests in early-stage digital health companies aligned with its "Informed Connected Health Consumer" thesis, providing both capital and hands-on operational support spanning strategy, go-to-market, operations, and culture building. In some cases the firm pursues a "Hatch" strategy, originating and building new ventures in-house. Notable portfolio companies include NOCD, WellTheory, Vivante Health, Homethrive, When, MedArrive, Transcarent, Zerigo Health, GroundGame.Health, Summer Health, 9amHealth, and Recora, and the firm counts the Livongo exit to Teladoc (valued at $18.5 billion) among its landmark outcomes.

The firm is not a technology product company and does not operate a proprietary software platform; its core offering is investment capital and operator-led company-building services delivered through its partnership, operating partners, and entrepreneur-in-residence. Its 2024-vintage Growth & Opportunity Fund closed at $217M+ and represents its primary capital deployment vehicle. Strategic Limited Partners include Cigna Ventures, which also co-invests in deals (e.g., co-leading NOCD's $34M Series C), providing both LP capital and payor channel access. Other recurring co-investors across the portfolio include Kaiser Permanente Ventures, F-Prime Capital, General Catalyst, Define Ventures, Accel, ManchesterStory, Mercato Partners, Telus Global Ventures, and Leaps by Bayer.

Revenue is generated through standard venture capital mechanics — management fees on committed capital across fund vintages and carried interest on successful portfolio exits. The firm has 11-50 employees and is headquartered at 444 N. Michigan Avenue in Chicago. Its content marketing, "Top of the Ladder" podcast, and annual predictions/perspectives serve as category-building tools that reinforce the firm's positioning as a thesis-driven digital health specialist. Management comprises co-founders Tullman and Shapiro as Managing Partners, Robert Garber (promoted to Managing Partner in 2024), Partner Alyssa Jaffee, Operating Partners Tom Richards and David Schonthal, EIR Dan Michelson, and Investment Principal Tiffany Yu.

Short descriptiontext

7wire Ventures is a Chicago-based early-stage digital health venture capital firm that invests in and actively builds companies creating Informed Connected Health Consumers, leveraging operator expertise from its Allscripts and Livongo alumni founders and a $217M+ Growth & Opportunity Fund closed in 2024.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersChicago, United States
HQ citystring
Chicago
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital health venture capital, early-stage healthcare investing, healthcare startup funding, venture capital firm, digital health portfolio
Industry3 codes
1Sector-Focused Venture Capital (Vertical Specialists)
CodeFSANAAADPrimaryYes
2Venture Studios / Company Builders
CodeFSANAAAHPrimaryNo
3Corporate Venture Studios & Incubators (Build/launch ventures)
CodeFSANAHACPrimaryNo
NAICS code2 codes
  • Other Investment Pools and Funds5259
  • Funds, Trusts, and Other Financial Vehicles525
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital / Private Equity
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Venture Capital Returns
TypeLicensing Royalties
Description

7wire Ventures generates returns through carried interest on successful portfolio company exits (acquisitions, IPOs). Their most notable success was Livongo (acquired by Teladoc for $18.5B). The firm takes an active operator approach, working closely with portfolio companies to drive growth and eventual exits.

7wireventures.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

7wire Ventures is an early-stage digital health venture capital firm that invests capital and provides hands-on operational support (strategy, GTM, operations, culture) to founders building companies that empower Informed Connected Health Consumers. It deploys dedicated investment vehicles — including a $217M+ Growth & Opportunity Fund — into digital health startups and, in select cases, uses a "Hatch" strategy to incubate new ventures in-house. The firm generates returns primarily through exits such as the Livongo acquisition by Teladoc.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Livongo acquired for $18.5B - largest digital health M&A transaction
Product overview1 text field

7wire Ventures is a venture capital firm that builds and invests in early-stage digital health companies dedicated to creating Informed Connected Health Consumers. Rather than a unified software product, the firm offers investment vehicles (Growth & Opportunity Fund, Hatch Strategy) and portfolio company investments. The firm works side-by-side with founders to build companies that empower consumers to be better stewards of their health. As company builders, the 7wire team has assumed highly involved roles, in some cases pursuing a Hatch strategy to start promising new ventures. The fund focuses on digital health companies that move consumers to the core of health and care.

Product and service3 records
1Growth & Opportunity Fund
CategoryInvestment fund
2Hatch Strategy
CategoryCompany-building service
3Portfolio Company Investment
CategoryVenture capital investment
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment78 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

7wire Ventures

Venture Capital / Private Equity7wireventures.com

7wire Ventures is a Chicago-based early-stage digital health venture capital firm that invests in and actively builds companies creating Informed Connected Health Consumers, leveraging operator expertise from its Allscripts and Livongo alumni founders and a $217M+ Growth & Opportunity Fund closed in 2024.

What 7wire Ventures does

7wire Ventures is a Chicago-based, privately-held venture capital firm founded circa 2013-2014 by Glen Tullman and Lee Shapiro, both former senior executives at Allscripts. The firm invests in early-stage digital health companies aligned with its "Informed Connected Health Consumer" thesis, providing both capital and hands-on operational support spanning strategy, go-to-market, operations, and culture building. In some cases the firm pursues a "Hatch" strategy, originating and building new ventures in-house. Notable portfolio companies include NOCD, WellTheory, Vivante Health, Homethrive, When, MedArrive, Transcarent, Zerigo Health, GroundGame.Health, Summer Health, 9amHealth, and Recora, and the firm counts the Livongo exit to Teladoc (valued at $18.5 billion) among its landmark outcomes.

The firm is not a technology product company and does not operate a proprietary software platform; its core offering is investment capital and operator-led company-building services delivered through its partnership, operating partners, and entrepreneur-in-residence. Its 2024-vintage Growth & Opportunity Fund closed at $217M+ and represents its primary capital deployment vehicle. Strategic Limited Partners include Cigna Ventures, which also co-invests in deals (e.g., co-leading NOCD's $34M Series C), providing both LP capital and payor channel access. Other recurring co-investors across the portfolio include Kaiser Permanente Ventures, F-Prime Capital, General Catalyst, Define Ventures, Accel, ManchesterStory, Mercato Partners, Telus Global Ventures, and Leaps by Bayer.

Revenue is generated through standard venture capital mechanics — management fees on committed capital across fund vintages and carried interest on successful portfolio exits. The firm has 11-50 employees and is headquartered at 444 N. Michigan Avenue in Chicago. Its content marketing, "Top of the Ladder" podcast, and annual predictions/perspectives serve as category-building tools that reinforce the firm's positioning as a thesis-driven digital health specialist. Management comprises co-founders Tullman and Shapiro as Managing Partners, Robert Garber (promoted to Managing Partner in 2024), Partner Alyssa Jaffee, Operating Partners Tom Richards and David Schonthal, EIR Dan Michelson, and Investment Principal Tiffany Yu.

7wire Ventures firmographics

Firmographics
Name
7wire Ventures
Legal name
7wire Ventures
Website
http://7wireventures.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
7wire Ventures is a Chicago-based early-stage digital health venture capital firm that invests in and actively builds companies creating Informed Connected Health Consumers, leveraging operator expertise from its Allscripts and Livongo alumni founders and a $217M+ Growth & Opportunity Fund closed in 2024.
Ownership category
akta.pro rank

7wire Ventures industry classification

Industry
Product category
Venture Capital / Private Equity
NAICS
Other Investment Pools and Funds (5259), Funds, Trusts, and Other Financial Vehicles (525)
SIC
Investment Advice (6282)
akta.pro primary industry
Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)
akta.pro secondary industries
Venture Studios / Company Builders (FSANAAAH), Corporate Venture Studios & Incubators (Build/launch ventures) (FSANAHAC)

Keywords

  • Digital health venture capital
  • Early-stage healthcare investing
  • Healthcare startup funding
  • Venture capital firm
  • Digital health portfolio

Where 7wire Ventures is headquartered

Location

Headquarters

HQ city
Chicago
HQ country
United States
HQ region
North America

Offices1 record

Markets served

7wire Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Venture Capital Returns: 7wire Ventures generates returns through carried interest on successful portfolio company exits (acquisitions, IPOs). Their most notable success was Livongo (acquired by Teladoc for $18.5B). The firm takes an active operator approach, working closely with portfolio companies to drive growth and eventual exits.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

7wire Ventures product offering

Product offering

Core offering

7wire Ventures is an early-stage digital health venture capital firm that invests capital and provides hands-on operational support (strategy, GTM, operations, culture) to founders building companies that empower Informed Connected Health Consumers. It deploys dedicated investment vehicles — including a $217M+ Growth & Opportunity Fund — into digital health startups and, in select cases, uses a "Hatch" strategy to incubate new ventures in-house. The firm generates returns primarily through exits such as the Livongo acquisition by Teladoc.

Product overview

7wire Ventures is a venture capital firm that builds and invests in early-stage digital health companies dedicated to creating Informed Connected Health Consumers. Rather than a unified software product, the firm offers investment vehicles (Growth & Opportunity Fund, Hatch Strategy) and portfolio company investments. The firm works side-by-side with founders to build companies that empower consumers to be better stewards of their health. As company builders, the 7wire team has assumed highly involved roles, in some cases pursuing a Hatch strategy to start promising new ventures. The fund focuses on digital health companies that move consumers to the core of health and care.

Differentiator

Problem solved

Functional benefit

Products and services

  • Growth & Opportunity Fund
  • Hatch Strategy
  • Portfolio Company Investment

Quantifiable outcome

  • Livongo acquired for $18.5B - largest digital health M&A transaction

Companies that use 7wire Ventures

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

7wire Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

7wire Ventures partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

7wire Ventures competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

7wire Ventures social profiles

Digital presence

7wire Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

7wire Ventures leadership team

Management profile

Number of profiles

Profiles10 records

7wire Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

7wire Ventures M&A and investment

M&A and investment

M&A1 record

Investments78 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 7wire Ventures

What does 7wire Ventures do?

7wire Ventures is an early-stage digital health venture capital firm that invests capital and provides hands-on operational support (strategy, GTM, operations, culture) to founders building companies that empower Informed Connected Health Consumers. It deploys dedicated investment vehicles — including a $217M+ Growth & Opportunity Fund — into digital health startups and, in select cases, uses a "Hatch" strategy to incubate new ventures in-house. The firm generates returns primarily through exits such as the Livongo acquisition by Teladoc.

Is 7wire Ventures a public or private company?

7wire Ventures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was 7wire Ventures founded?

7wire Ventures was founded in 2011. It employs 11 to 50 people.

Where is 7wire Ventures based?

7wire Ventures is headquartered in Chicago, United States, in the North America region.

How does 7wire Ventures make money?

One revenue line is on record: venture Capital Returns.

Does 7wire Ventures have an API?

No public API is recorded for 7wire Ventures.

What industry is 7wire Ventures in?

7wire Ventures's product category is Venture Capital / Private Equity. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists), with a secondary code of FSANAAAH, Venture Studios / Company Builders. Its NAICS code is 5259 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinSMEsKaroo Health Raises $16.2M in Series A FundingKaroo Health, an Albuquerque-based cardiovascular technology company, raised $16.2M in Series A funding led by 7wire Ventures and Allumia Ventures. The company will use the funds to expand operations and R&D, and its platform connects payers, providers, and patients across 600+ cardiology providers in 11 states.PR NewswireKaroo Health Announces Oversubscribed $16.2 Million Series A Co-Led by 7wire Ventures and Allumia VenturesKaroo Health, a cardiovascular technology company, announced the closing of a $16.2 million Series A financing round co-led by 7wire Ventures and Allumia Ventures, with participation from First Trust Capital Partners, SpringRock Ventures, and Hyde Park Angels. The company is building an AI-native platform connecting payers, providers, and patients, currently supporting over 600 cardiology providers across 11 states. Karoo plans to use proceeds to further develop its platform, expand engineering and clinical teams, and scale deployments with payer and provider partners.BioSpaceKaroo Health Announces Oversubscribed $16.2 Million Series A Co-Led by 7wire Ventures and Allumia VenturesKaroo Health closed a $16.2 million Series A co-led by 7wire Ventures and Allumia Ventures, with participation from other investors. The company will use proceeds to develop its AI-native cardiovascular platform and expand partnerships. Deployed programs have shown over 40% reductions in emergency visits and inpatient admissions.7wireVenturesAnish Aitharaju Joins 7wire Ventures as Investment Principal7wire Ventures has appointed Anish Aitharaju as an Investment Principal to focus on early-stage healthcare and digital health investments. Aitharaju joins from DigiTx Partners, bringing prior experience in business development at Twill and Click Therapeutics.BloombergVanguards of Health Care: 7Wire’s Thesis On Empowering ConsumersThe article discusses 7Wire Ventures' approach to healthcare investment, emphasizing the importance of engaging end consumers for impactful outcomes. Alyssa Jaffee highlights opportunities in women's health, AI, and fixing systemic issues in healthcare.BhbusinessThe Case for Going Niche in Behavioral HealthThis BHB+ opinion piece argues that new behavioral health providers should start with specific, narrow conditions rather than broad mental health services. The article cites NOCD as a leading example—a startup launched in 2018 focused exclusively on obsessive-compulsive disorder that raised approximately $84 million from investors including Cigna Ventures, 7wireVentures, Kaiser Permanente Ventures, and F-Prime Capital, and achieved its first month of positive EBITDA before expanding. In March 2025, NOCD announced the acquisition of trauma care provider Rebound Health and simultaneously restructured both companies under a new parent company called Noto, positioning itself as a specialty behavioral health provider for complex psychiatric conditions.EIN PresswireWhen raises $10M Series A to transform employee health benefits during critical momentsWhen, a workforce transitions platform focused on reducing healthcare costs during employee job changes, has raised $10.2 million in Series A funding co-led by ManchesterStory and 7wire Ventures, with participation from Mairs & Power Venture Capital and existing investors including B Capital, Enfield Capital Partners, TTV Capital, and Alumni Ventures. The company, founded in 2020 by former Expedia Group and Target leaders who experienced layoffs and costly COBRA insurance, reported 4X year-over-year revenue growth, 6,200+ customer companies, and over 1 million eligible employee users since its January 2024 launch. When plans to use the funding to expand its team and offerings to support a wider range of coverage transitions including career changes, Medicare eligibility, and early retirements.YahooAI Startup WellTheory Raises $14 Million From General Catalyst, Accel, 7wire Ventures To Transform Autoimmune Health For Millions Of PatientsWellTheory, a female-founded AI health startup, raised $14 million in Series A funding led by General Catalyst. The company targets the $180 billion autoimmune market, with membership growing over tenfold in the past year. The funds will support enterprise partnerships and AI system development.SecSEC FORM D7wire Ventures Fund III, L.P., a Delaware-registered venture capital fund based in Chicago, Illinois, filed a Form D with the SEC notifying regulators of an exempt offering of securities with a target amount of $150 million. The filing indicates the fund has already sold approximately $81 million to 36 investors as of October 6, 2025, with $69 million remaining to be sold. The fund, which qualifies as a pooled investment fund under Rule 506(c), intends for the offering to continue beyond one year.7wireVentures7wire Ventures Presents: Top of the Ladder Featuring Zerigo Health CEO Lisa Rometty7wire Ventures featured Zerigo Health CEO Lisa Rometty in its 'Top of the Ladder' series to discuss the company's digital health platform for treating chronic skin conditions. The article highlights Zerigo's FDA-cleared home phototherapy device, which aims to improve patient access and reduce costs compared to traditional clinic treatments or expensive biologics.